[1]Patent:WO2015/6875,2015,A1,.Locationinpatent:Paragraph0274;0275
[2]JournalofMedicinalChemistry,2008,vol.51,#14,p.4072-4075
[3]JournalofMedicinalChemistry,2013,vol.56,#15,p.6156-6174
[1]JournalofMedicinalChemistry,2013,vol.56,#15,p.6156-6174
[1]JournalofMedicinalChemistry,2013,vol.56,#15,p.6156-6174
[1]JournalofMedicinalChemistry,2013,vol.56,#15,p.6156-6174
[1]Patent:WO2015/6875,2015,A1,
[1]Patent:WO2015/6875,2015,A1.Locationinpatent:Paragraph0274;0275
[2]JournalofMedicinalChemistry,2008,vol.51,p.4072-4075
[3]JournalofMedicinalChemistry,2013,vol.56,p.6156-6174
[1]JournalofMedicinalChemistry,2013,vol.56,p.6156-6174
[1]JournalofMedicinalChemistry,2013,vol.56,p.6156-6174
[1]JournalofMedicinalChemistry,2013,vol.56,p.6156-6174
Title: Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20160901
Title: Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
Journal: Oncotarget 20151020
Title: Natural indoles, indole-3-carbinol and 3,3'-diindolymethane, inhibit T cell activation by staphylococcal enterotoxin B through epigenetic regulation involving HDAC expression.
Journal: Toxicology and applied pharmacology 20140101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
Journal: Journal of medicinal chemistry 20121126
Title: Novel agents in Hodgkin lymphoma.
Journal: Current oncology reports 20121001
Title: An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Journal: Cancer chemotherapy and pharmacology 20120601
Title: Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Journal: Cancer biology & therapy 20120601
Title: Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.
Journal: Circulation research 20120302
Title: Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Journal: The Lancet. Oncology 20111201
Title: Histone deacetylase inhibitors and Hodgkin's lymphoma.
Journal: The Lancet. Oncology 20111201
Title: Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
Journal: Journal of medicinal chemistry 20110714
Title: The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.
Journal: Oncogene 20110707
Title: Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.
Journal: Cancer science 20110601
Title: Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
Journal: Expert opinion on investigational drugs 20110601
Title: Clinical development of panobinostat in classical Hodgkin's lymphoma.
Journal: Expert review of hematology 20110601
Title: Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Journal: Cytotherapy 20110501
Title: Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.
Journal: Bioorganic & medicinal chemistry letters 20110101
Title: Interpreting clinical assays for histone deacetylase inhibitors.
Journal: Cancer management and research 20110101
Title: Histone deacetylase inhibitors in Hodgkin lymphoma.
Journal: Investigational new drugs 20101201
Title: Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
Journal: Investigational new drugs 20101201
Title: The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Journal: British journal of haematology 20101101
Title: Histone deacetylase inhibitors in the treatment of lymphoma.
Journal: Discovery medicine 20101101
Title: The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.
Journal: Oncotarget 20101101
Title: The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Journal: Autophagy 20101001
Title: The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.
Journal: Molecular pharmacology 20100901
Title: The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100801
Title: Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Journal: Molecular cancer therapeutics 20100801
Title: The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.
Journal: Molecular cancer therapeutics 20100501
Title: [New approach to determine the pharmacodynamic effects of histone deacetylases inhibitors].
Journal: Pharmazie in unserer Zeit 20100501
Title: Effect of antioxidants on airway smooth muscle contraction: action of lipoic acid and some of its novel derivatives on guinea pig tracheal smooth muscle.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20100301
Title: Effect of endogenous and synthetic antioxidants on hydrogen peroxide-induced guinea-pig colon contraction.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20100301
Title: Chemical phylogenetics of histone deacetylases.
Journal: Nature chemical biology 20100301
Title: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
Journal: Journal of hematology & oncology 20100101
Title: Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.
Journal: British journal of haematology 20091101
Title: Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20091001
Title: Clinical studies of histone deacetylase inhibitors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
Title: Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Journal: Anti-cancer drugs 20090601
Title: A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
Journal: International journal of radiation oncology, biology, physics 20090301
Title: SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
Journal: Bioorganic & medicinal chemistry letters 20090201
Title: Sulfamides as novel histone deacetylase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20090115
Title: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Journal: Journal of hematology & oncology 20090101
Title: Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Journal: International immunopharmacology 20081220
Title: Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Journal: Blood 20080815
Title: Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.
Journal: Expert opinion on investigational drugs 20080801
Title: Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.
Journal: Journal of medicinal chemistry 20080724
Title: Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080601
Title: Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080420
Title: MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Journal: Molecular cancer therapeutics 20080401
Title: Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
Journal: Bioorganic & medicinal chemistry letters 20080315
Title: Histone deacetylase inhibitors in lymphoma and solid malignancies.
Journal: Expert review of anticancer therapy 20080301
Title: Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20080201
Title: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Journal: The Biochemical journal 20080115
Title: Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group.
Journal: International journal of cancer 20070901
Title: Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Journal: Current opinion in investigational drugs (London, England : 2000) 20070601
Title: Fournel M, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008 Apr;7(4):759-68.
Title: Cai J, et al. The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method. Biomed Res Int. 2015;2015:517295.
